- Market Capitalization, $K 43,904
- Shares Outstanding, K 38,177
- Annual Sales, $ 0 K
- Annual Income, $ -29,370 K
- 60-Month Beta 3.72
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 3.37
|Period||Period Low||Period High||Performance|
| || |
-0.0400 (-3.36%)since 06/05/20
| || |
+0.8350 (+265.08%)since 04/07/20
| || |
+0.4500 (+64.29%)since 07/05/19
-- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy's off-target effects --
Aileron Therapeutics (NASDAQ: ALRN) announced today the closing of its underwritten public offering of its common stock, including the exercise by the underwriter of their option to purchase an additional...
Aileron Therapeutics (NASDAQ: ALRN) announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $1.10 per share, for aggregate gross...
Aileron Therapeutics (NASDAQ: ALRN) announced today that it has commenced an underwritten public offering of shares of its common stock. Aileron also intends to grant the underwriter a 30-day option to...
The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OVID, CLSN, ALRN, CRON, and BAC.
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
- - -
Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients...